MADISON, Wis., June 12, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the Accuray Precision® Treatment Planning System (TPS) has been approved by the Chinese National Medical Products Administration (NMPA). The Accuray Precision TPS is now available for use with the CNNC-Accuray joint venture Tomo® C radiation therapy system and in combination, will provide medical care teams with a new option for delivering extremely precise and accurate radiothe ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:3D Systems Corporation (DDD) is 3D printing solutions company. The Zacks Consensus Estimate for its current year earnings has been revised 11.1% downward over the last 60 days.Accuray Incorporated (ARAY) is a radiation oncology company. The Zacks Consensus Estimate for its current year earnings has been revised 128.6% downward over the last 60 days.Brenntag SE (BNTGY) is a chemical distribution company.The Zacks Consensus Estimate for ...

MADISON, Wis., May 22, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2024. The management team is scheduled to participate in a fireside chat on Wednesday, June 5, 2024 at 7:30am EDT/4:30am PDTA live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available for 90 days.About ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share ARAY The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission F ...

Accuray Incorporated (ARAY) reported a loss per share of 6 cents for the third quarter of fiscal 2024 against the year-ago period’s earnings per share (EPS) of a penny. The metric was also wider than the Zacks Consensus Estimate of a loss of a penny per share.Revenues in DetailAccuray registered revenues of $101.1 million in the third quarter of fiscal 2024, down 14.3% year over year. The figure lagged the Zacks Consensus Estimate by 11.8%.The overall top-line growth was dampened by lower revenues from both ...

Accuray Incorporated (NASDAQ:ARAY) Q3 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Jesse Chew - SVP and Chief Legal Officer Suzanne Winter - President and CEO Ali Pervaiz - CFO Conference Call Participants Young Li - Jefferies Brooks O'Neil - Lake Street Jason Wittes - ROTH MKM Operator Good afternoon, and welcome to the Accuray conference call to review financial results for the third quarter of fiscal year 2024 which ended March 31 of 2024. All participants will be in listen-o ...

分组1 - Accuray reported a quarterly loss of $0.06 per share, missing the Zacks Consensus Estimate of a loss of $0.01, and compared to earnings of $0.01 per share a year ago, indicating an earnings surprise of -500% [1] - The company's revenues for the quarter ended March 2024 were $101.13 million, missing the Zacks Consensus Estimate by 11.75%, and down from $118.06 million year-over-year [1] - Accuray has not surpassed consensus EPS estimates over the last four quarters, and has topped consensus revenue estimates only twice in the same period [1] 分组2 - Accuray shares have declined approximately 24.7% since the beginning of the year, contrasting with the S&P 500's gain of 5.6% [2] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [2] - The current consensus EPS estimate for the next quarter is $0.07 on revenues of $137.8 million, and for the current fiscal year, it is -$0.07 on revenues of $463.5 million [4] 分组3 - The Zacks Industry Rank places Medical - Instruments in the bottom 44% of over 250 Zacks industries, indicating potential underperformance compared to the top 50% of ranked industries [4] - The trend of estimate revisions for Accuray is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market [3]

Exhibit 99.1 Accuray Reports Fiscal 2024 Third Quarter Financial Results MADISON, Wis, May 1, 2024 — Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter and nine-months ended March 31, 2024. Third Quarter Fiscal 2024 Summary • Net revenue of $101.1 million decreased 14 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $102.4 million, which represented a 13 percent decrease from the same period in the prior fiscal year. ...

Celebrates 30 Years of Innovation Through Collaboration and the Development of Technologies That Have Helped Set the Standard of Care for the Industry MADISON, Wis., April 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company is showcasing advances in hardware and software designed to improve the cancer treatment experience, at ESTRO 2024. The latest generation CyberKnife® and Radixact® platforms provide medical care teams with the technology necessary for expanding t ...

 The new center is the most recent addition to the company's existing training hubs in Madison, Wisconsin (U.S.), Tokyo, Japan and Tianjin, China  Each facility offers a range of educational opportunities designed to advance patient care using the Accuray CyberKnife® and Radixact® Systems MADISON, Wis., April 18, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that as part of its commitment to advancing patient care the company has opened a new training center in Genolier, Switzer ...